Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

20265 citationsJournal Article

Authors

Sara M Tolaney · Harvard University

E. de Azambuja · Institut Jules Bordet

Kevin Kalinsky · Emory University

Sherene Loi · The University of Melbourne

Sung-Bae Kim · Ulsan College

Clinton Yam · The University of Texas MD Anderson Cancer Center

Bernardo L. Rapoport ·

Abstract

Sacituzumab govitecan plus pembrolizumab led to significantly longer progression-free survival than chemotherapy plus pembrolizumab among patients with previously untreated, PD-L1-positive, advanced triple-negative breast cancer. (Funded by Gilead Sciences; ASCENT-04/KEYNOTE-D19 ClinicalTrials.gov number, NCT05382286.).

Topics & Keywords

Cancer Immunotherapy and Biomarkers HER2/EGFR in Cancer Research Advanced Breast Cancer Therapies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 394, Issue 4, pp. 354-366

DOI: 10.1056/nejmoa2508959

Field-Weighted Citation Impact: 113.04